Malignant Pineal Parenchymal Tumors in Adults: A National Cancer Database Analysis
- PMID: 35311743
- DOI: 10.1227/neu.0000000000001915
Malignant Pineal Parenchymal Tumors in Adults: A National Cancer Database Analysis
Abstract
Background: Limited retrospective data exist on malignant pineal parenchymal tumors (PPTs) in adults, and there are no large previous studies that review clinical outcomes across the 3 treatment arms of surgery, radiotherapy, and chemotherapy. As a result, optimal disease management has yet to be defined.
Objective: To evaluate treatment trends and perform survival analysis in adult PPT.
Methods: The National Cancer Database was queried for histologically confirmed PPT diagnosed from 2007 to 2016. Univariate and multivariate Cox regressions were used to evaluate the prognostic impact of covariates. Kaplan-Meier survival curves were generated for comparative subanalyses.
Results: Of the 251 patients who met inclusion criteria, 172 had PPTs of intermediate differentiation (PPTID) and 79 had pineoblastoma. A plurality of patients with pineoblastoma were treated with trimodal therapy (39.1%), whereas patients with PPTID were commonly treated with either surgery alone or surgery and radiation (33.7% each). Factors independently associated with improved overall survival include younger patient age, female sex, lower comorbidity score, lower tumor grade, and treatment with surgery or radiation (each P < .05). Subanalyses confirm the effect of radiation on survival in patients with grade III PPTID with subtotal resection; however, no survival benefit of adjuvant radiation is demonstrated in patients with grade II PPTID with subtotal resection.
Conclusion: Although radiotherapy and surgery were found to increase survival in all patients with PPT, there was no demonstrable survival benefit of adjuvant radiation in surgically treated patients with grade II PPTID. This suggests that adjuvant radiotherapy may not add significant survival benefit in many adult patients with grade II PPTID.
Copyright © Congress of Neurological Surgeons 2022. All rights reserved.
Comment in
-
Commentary: Malignant Pineal Parenchymal Tumors in Adults: A National Cancer Database Analysis.Neurosurgery. 2022 Jun 1;90(6):e146. doi: 10.1227/neu.0000000000001987. Epub 2022 Apr 12. Neurosurgery. 2022. PMID: 35394460 No abstract available.
-
Commentary: Malignant Pineal Parenchymal Tumors in Adults: A National Cancer Database Analysis.Neurosurgery. 2022 Sep 1;91(3):e97-e99. doi: 10.1227/neu.0000000000002068. Epub 2022 Jul 8. Neurosurgery. 2022. PMID: 35876677 No abstract available.
Similar articles
-
Prognosticating survival of pineal parenchymal tumors of intermediate differentiation (PPTID) by grade.J Neurooncol. 2021 Nov;155(2):165-172. doi: 10.1007/s11060-021-03863-y. Epub 2021 Oct 4. J Neurooncol. 2021. PMID: 34606044
-
Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome.Neuro Oncol. 2017 Jan;19(1):78-88. doi: 10.1093/neuonc/now105. Epub 2016 Jun 9. Neuro Oncol. 2017. PMID: 27282397 Free PMC article.
-
Clinicopathologic study of pineal parenchymal tumors of intermediate differentiation.World Neurosurg. 2014 May-Jun;81(5-6):783-9. doi: 10.1016/j.wneu.2013.02.007. Epub 2013 Feb 8. World Neurosurg. 2014. PMID: 23396072
-
Pineal Parenchymal Tumor of Intermediate Differentiation (PPTID) and Papillary Tumor of Pineal Region (PTPR): A Review.Neurol India. 2021 Sep-Oct;69(5):1153-1164. doi: 10.4103/0028-3886.329550. Neurol India. 2021. PMID: 34747779 Review.
-
Patterns of care and survival outcomes in patients with pineal parenchymal tumor of intermediate differentiation: An individual patient data analysis.Radiother Oncol. 2016 Nov;121(2):204-208. doi: 10.1016/j.radonc.2016.10.025. Epub 2016 Nov 16. Radiother Oncol. 2016. PMID: 27865543 Review.
Cited by
-
Pineal parenchymal tumor of intermediate differentiation: Case series and literature review: Is it time for a consensus?Surg Neurol Int. 2025 Apr 18;16:138. doi: 10.25259/SNI_1068_2024. eCollection 2025. Surg Neurol Int. 2025. PMID: 40353160 Free PMC article.
-
Survival and Malignant Transformation of Pineal Parenchymal Tumors: A 30-Year Retrospective Analysis in a Single-Institution.Brain Tumor Res Treat. 2023 Oct;11(4):254-265. doi: 10.14791/btrt.2023.0033. Brain Tumor Res Treat. 2023. PMID: 37953449 Free PMC article.
References
-
- Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231-1251.
-
- Sonabend AM, Bruce JN. Management paradigms along a histologic spectrum of pineal cell tumors. World Neurosurg. 2014;81(5-6):685-687.
-
- Raleigh DR, Solomon DA, Lloyd SA, et al. Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome. Neuro Oncol. 2017;19(1):78-88.
-
- Clark AR, Calligaris D, Regan MS, et al. Rapid discrimination of pediatric brain tumors by mass spectrometry imaging. J Neurooncol. 2018;140(2):269–279.
-
- Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24(25):4202-4208.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous